Latest Breaking News On - Clin urol - Page 1 : comparemela.com

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

/PRNewswire/ Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of.

United kingdomUnited statesSan antonioAnia diantonioIndianj urolJoseph jacobPrnewswire johnsonClin urolJanssen research developmentAmerican cancer societyEuropean association of urologyEuropean society for medical oncologyBladder cancer advocacy networkDrug administrationNone of janssen research developmentExchange commission

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer
bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesUnited kingdomJoseph jacobClin urolIndianj urolAnia diantonioDepartment of urologyEuropean association of urologyEuropean society for medical oncologyDrug administrationExchange commissionAmerican cancer societyJanssen research developmentBladder cancer advocacy networkAmerican urological association annual meeting

Johnson & Johnson s Investigational TAR-200 Granted U S FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD).

United statesUnited kingdomObrian kenneyClin urolKiran patelIndianj urolPrnewswire johnsonExchange commissionJanssen biotech incDrug administrationJanssen research developmentEuropean society for medical oncology annual congressAmerican urological association annual meeting abstractNone of janssen research developmentClinical developmentBreakthrough therapy designation

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 .

United kingdomJames wf cattoIndianj urolClin urolObrian kenneyKiran patelJnjinnovmedand janssenExchange commissionDrug administrationClinical developmentCompanies of johnsonEuropean society for medical oncologyDepartment of oncologyEuropean society for medical oncology congressNone of janssen research developmentJanssen research development

TAR-200 Intravesical Delivery System Results Show 77 Percent Complete Response Rate in Patients with Bacillus-Calmette-Guérin Unresponsive, High-Risk Non-Muscle-Invasive Bladder Cancer

Phase 2b SunRISe-1 study results showed sustained, durable complete responses beyond one year with intravesical gemcitabine delivery system MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that data from the Phase 2b SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, […]

United kingdomUnited statesObrian kenneyClin urolAndrea necchiScientific instituteNone of janssen research developmentJanssen research developmentExchange commissionSalute san raffaele universityEuropean society for medical oncologyJanssen pharmaceutical companies of johnsonAmerican urological association annual meetingJanssen biotech incCompanies of johnsonJanssen pharmaceutical companies